Maxim Weekly Maxim Weekly

Apple saw Valley National Advisers trim its position by about 13% in Q3, one example of small institutional rotation even as institutions still own roughly 68% of the company. The coverage highlighted potential catalysts including late-season iPhone 17 demand, Apple Card's transition to JPMorgan, continued services momentum, and Apple's AI roadmap, supported by a recent earnings beat. Key risks flagged were app-store regulatory scrutiny, intensifying AI competition, and insider selling, even as consensus remained a Moderate Buy with an average target around $284.

Dexcom reported preliminary, unaudited Q4 2025 revenue of about $1.26B, up 13% year over year, with US revenue around $892M, up 11%, topping the high end of guidance. The company's 2026 catalysts include the G7 15-Day sensor launch, Stelo rollout, international expansion, and AI-powered features, alongside guidance of $5.16B to $5.25B in revenue. At the same time, investors are watching a new CEO transition, remediation of G7 quality issues, an FDA warning, two Class I recalls, and ongoing litigation, with conference commentary and Medicare competitive-bidding dynamics also in focus.

Truist saw institutions both adding to and trimming positions, with ownership around 71%, suggesting active but not one-directional positioning. The bullish supports cited were a $10B buyback authorization, a roughly 4.1% to 4.2% dividend yield, and recent modest earnings beats, while analyst views clustered around Hold with targets in the low-to-high $50s. The coverage emphasized that the setup may appeal more to income-oriented investors, but that loan quality, payout sustainability, and bank-sector risks remain key variables.

Autodesk saw some trimming by select holders, but broader institutional ownership remained very high, around 90%, with several large firms adding or initiating positions. The company beat Q3 estimates and raised FY26 guidance, while the coverage pointed to AI features, cloud migration, and usage-based billing as key catalysts, with investors watching subscription growth, net retention, and operating leverage. Despite optimistic analyst targets around $370 in parts of the coverage, valuation remained a central caution, with a high P/E in the low-50s and the stock trading below key moving averages in one report.

AMETEK coverage emphasized resilient execution, including a report of Q1 sales up 20% to $1.46B and adjusted EPS up 24% to $1.33, with orders up 22% and backlog at a record $3.0B, alongside raised adjusted EPS guidance. Separate commentary framed AMETEK as a lower-volatility industrial-tech compounder supported by recurring revenue and disciplined bolt-on M&A, while also noting valuation risk if growth cools. Institutional activity was mixed, with one large holder trimming modestly even as other major institutions added, and the stock's small dividend and mentions of insider selling tempered enthusiasm.